Evidence map›Paper›PMID 36241930›Full record

Trial reportInternational journal of clinical oncology2022

Phase I/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: Kanto Respiratory Disease Study Group (KRSG) 1302.

Takashi Kasai, Kiyoshi Mori, Tomohide Sugiyama, Nobuyuki Koyama, Yoichi Nakamura, Fumiyoshi Ohyanagi, Hiroki Fukuda, Eishin Hoshi, Kunihiko Kobayashi, Mitsuo Nakayama

Abstract readClinical Trial, Phase IIClinical Trial, Phase I
PubMed Publisher
In one paragraph

Trial report in International journal of clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Takashi KasaiDivision of Thoracic Oncology, Department of Medical Oncology, Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, Tochigi, Japan. takasai@tochigi-cc.jp.ORCID http://orcid.org/0000-0002-3112-4001
Kiyoshi MoriDivision of Thoracic Oncology, Department of Thoracic Diseases, Utsunomiya Memorial Hospital, Tochigi, Japan.
Tomohide SugiyamaDivision of Thoracic Oncology, Department of Medical Oncology, Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, Tochigi, Japan.
Nobuyuki KoyamaDepartment of Respiratory Medicine, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Yoichi NakamuraDivision of Thoracic Oncology, Department of Medical Oncology, Tochigi Cancer Center, 4-9-13 Yonan, Utsunomiya, Tochigi, Japan.
Fumiyoshi OhyanagiDepartment of Respiratory Medicine, Saitama Cancer Center, Saitama, Japan.
Hiroki FukudaDepartment of General Thoracic Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Eishin HoshiDepartment of General Thoracic Surgery, Saitama Cardiovascular and Respiratory Center, Saitama, Japan.
Kunihiko KobayashiDepartment of Respiratory Medicine, Saitama Medical University International Medical Center, Saitama, Japan.
Mitsuo NakayamaDepartment of General Thoracic Surgery, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
Social Insurance Saitama Chuo Hospital · JPTochigi Cancer Center · JPSaiseikai Utsunomiya hospital · JPSaitama Cancer Center · JPSaitama Medical University · JPSaitama Prefecture · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundNedaplatin and nab-paclitaxel are each efficacious in the treatment of squamous cell lung cancer. PATIENTS AND

methodsEligibility criteria were: no prior chemotherapy, advanced squamous cell lung cancer; performance status 0-1, age > 20 years but < 75 years, and adequate hematologic, hepatic and renal function. Patients received escalating doses of nab-paclitaxel under a fixed dose of nedaplatin (100 mg/m

resultsIn phase I, three patients at level 1 experienced no dose-limiting toxicities (DLTs) and two patients at level 2 experienced DLTs. Level 1 was thus determined as the recommended dose. Twenty-three patients were enrolled in phase II. The 3 patients in level 1 and 23 patients in phase II were included together for analyses. Three of these 26 patients were excluded from response analysis due to pneumonia and patient refusal. Response rate was 91.3% (95% confidence interval, 72.0-98.9%). Toxicities observed during all cycles were tolerable.

conclusionsThe recommended dose for this combination was nedaplatin at 100 mg/m

Indexed as

Carcinoma, Non-Small-Cell LungCarcinoma, Squamous CellLung NeoplasmsAdultAlbuminsAntineoplastic Combined Chemotherapy ProtocolsEpithelial CellsHumansOrganoplatinum CompoundsPaclitaxelYoung Adult130-nm albumin-bound paclitaxelAlbuminsnedaplatinOrganoplatinum CompoundsPaclitaxelNab-paclitaxelNedaplatinPhase I/II studyPlatinum compoundSquamous cell lung cancer

Identifiers

PMID36241930
OpenAlexW4306252728

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.